Short interest in Madrigal Pharmaceuticals rose to a four-month high, Ortex data showed, as bearish positions increased ...

Aroosha Sarrafi tells Health her story of getting diagnosed with metabolic dysfunction-associated steatohepatitis (MASH), a ...

Fatty liver disease, also called metabolic dysfunction-associated steatohepatitis (MASH), is a condition where fat ...

Analysis of EFX results with AI-based digital pathology underscores the potential value in evaluating histopathology response ...

Fact checked by Nick Blackmer I was first told that I was at higher risk for fatty liver disease in 2005. I had never heard ...

Pregnant women with metabolic dysfunction-associated steatotic liver disease (MASLD) have an increased risk of giving birth prematurely and the risk increase cannot be explained by obesity, according ...

Naim Alkhouri, MD, spoke to the potential for glucagon-like peptide-1 (GLP-1) receptor agonists to transform the treatment ...

From 2006 to 2019, age-adjusted mortality for liver disease in the US increased by 14% overall and by 24% during COVID, from 2019 through 2021.

Once-monthly efimosfermin alfa prescribed for metabolic dysfunction–associated steatohepatitis with F2 and F3 fibrosis ...

Results support potential benefit of efruxifermin (EFX) to elicit fibrosis improvement in patients with compensated cirrhosis (F4 fibrosis) due to MASH 96-week data from SYMMETRY trial presented at EA ...

Biomedical research in liver diseases has traditionally depended on animal models, but ethical concerns and the quest for ...